(Bloomberg) -- GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles ...

Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2025 in San Francisco. | Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2025 in San Francisco. Yesterday saw some high-value ...

The anti-vaccine movement in the U.S. has gained momentum with President-elect Donald Trump's nomination of Robert F. Kennedy ...

GlaxoSmithKline’s CEO Emma Walmsley has said the company hopes to get at least six new drug approvals in the next year. In an interview at the JP Morgan Healthcare Conference in San Francisco ...

GlaxoSmithKline (GSK) has appointed its consumer health leader, Emma Walmsley, to take over as CEO when Sir Andrew Witty retires next year. Walmsley has a background in marketing, and joined GSK ...

Walmsley, the only woman CEO of a major pharma company, told Fortune at the time that GSK was working on building its vaccine portfolio. That’s not the only avenue where GSK is growing.

Ana Botin, executive chair of Spanish bank Santander has denied reports that the company is considering leaving the British ...

GSK Plc CEO Emma Walmsley talks about buying US cancer biotech IDRx for as much as $1.15 billion, expanding their portfolio in the US, their overall drug pipeline and working with Robert F. Kennedy Jr ...

Emma Walmsley, CEO of GSK, is nearly eight years into her effort to return the British pharma company to growth, and her work is starting to pay off. Much credit goes to Arexvy, GSK’s first-on ...

GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its return to cancer medicines. While GSK already agreed to multiple deals in ...

Emma Walmsley would like to see Prime Minister Narendra Modi creating a nutrition programme similar to the cleanliness drive Swachh Bharat. Get updates on your preferred social platform Follow us ...